Compare GGB & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GGB | QGEN |
|---|---|---|
| Founded | 1901 | 1986 |
| Country | Brazil | Netherlands |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.2B |
| IPO Year | 2000 | 1998 |
| Metric | GGB | QGEN |
|---|---|---|
| Price | $4.86 | $33.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $5.38 | ★ $45.76 |
| AVG Volume (30 Days) | ★ 18.3M | 1.9M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | 2.30% | ★ 7.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.59 | $8.18 |
| Revenue Next Year | $3.46 | $5.71 |
| P/E Ratio | ★ $13.89 | $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.61 | $33.17 |
| 52 Week High | $4.98 | $57.82 |
| Indicator | GGB | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 71.12 | 24.85 |
| Support Level | $2.84 | N/A |
| Resistance Level | N/A | $49.16 |
| Average True Range (ATR) | 0.13 | 0.92 |
| MACD | 0.03 | -0.28 |
| Stochastic Oscillator | 83.35 | 1.56 |
Gerdau SA produces steel and steel products. The company operates in civil construction, agriculture, automotive, iron ore, exports, research and development, and home steel products sectors. It offers products such as nails, rebar, columns, billets, slabs, tribar tutors, mechanical construction bars, and reinforced steel locks. The company's geographical segment includes Brazil Segment; North America Segment; South America Segment as well as Special Steel Operations. It derives the majority of its revenue from the Brazil Operations segment, which includes the long, flat and special steel operations and the iron ore operation located in Brazil and joint ventures and associated companies located in Brazil.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).